121 related articles for article (PubMed ID: 19900495)
21. A 4-arm polyethylene glycol derivative conjugated with exendin-4 peptide and palmitylamine having dual-function of size-increase and albumin-binding for long hypoglycemic action.
Kim I; Kim TH; Ma K; Park ES; Oh KT; Lee ES; Lee KC; Youn YS
Regul Pept; 2011 Apr; 167(2-3):239-45. PubMed ID: 21329731
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy.
Kim I; Kim TH; Ma K; Lee ES; Kim D; Oh KT; Lee DH; Lee KC; Youn YS
Bioconjug Chem; 2010 Aug; 21(8):1513-9. PubMed ID: 20715855
[TBL] [Abstract][Full Text] [Related]
23. A site-specific PEGylated analog of exendin-4 with improved pharmacokinetics and pharmacodynamics in vivo.
Gao M; Jin Y; Tong Y; Tian H; Gao X; Yao W
J Pharm Pharmacol; 2012 Nov; 64(11):1646-53. PubMed ID: 23058052
[TBL] [Abstract][Full Text] [Related]
24. Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions.
Sasson K; Marcus Y; Lev-Goldman V; Rubinraut S; Fridkin M; Shechter Y
J Control Release; 2010 Mar; 142(2):214-20. PubMed ID: 19883707
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
Irwin N; Clarke GC; Green BD; Greer B; Harriott P; Gault VA; O'Harte FP; Flatt PR
Biochem Pharmacol; 2006 Sep; 72(6):719-28. PubMed ID: 16859646
[TBL] [Abstract][Full Text] [Related]
26. Pulmonary administered palmitic-acid modified exendin-4 peptide prolongs hypoglycemia in type 2 diabetic db/db mice.
Lee J; Lee C; Kim TH; Chi SC; Moon HR; Oh KT; Lee ES; Lee KC; Youn YS
Regul Pept; 2012 Aug; 177(1-3):68-72. PubMed ID: 22561689
[TBL] [Abstract][Full Text] [Related]
27. Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice.
Kim TH; Park CW; Kim HY; Chi MH; Lee SK; Song YM; Jiang HH; Lim SM; Youn YS; Lee KC
Biol Pharm Bull; 2012; 35(7):1076-83. PubMed ID: 22791155
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
Gedulin BR; Smith PA; Jodka CM; Chen K; Bhavsar S; Nielsen LL; Parkes DG; Young AA
Int J Pharm; 2008 May; 356(1-2):231-8. PubMed ID: 18291606
[TBL] [Abstract][Full Text] [Related]
29. Micellar Nanomedicine of Novel Fatty Acid Modified Xenopus Glucagon-like Peptide-1: Improved Physicochemical Characteristics and Therapeutic Utilities for Type 2 Diabetes.
Han J; Fei Y; Zhou F; Chen X; Zheng W; Fu J
Mol Pharm; 2017 Nov; 14(11):3954-3967. PubMed ID: 28945431
[TBL] [Abstract][Full Text] [Related]
30. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice.
Youn YS; Jeon JE; Chae SY; Lee S; Lee KC
Diabetes Obes Metab; 2008 Apr; 10(4):343-6. PubMed ID: 18034839
[TBL] [Abstract][Full Text] [Related]
31. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
Gallwitz B
Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
[TBL] [Abstract][Full Text] [Related]
32. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.
Mack CM; Moore CX; Jodka CM; Bhavsar S; Wilson JK; Hoyt JA; Roan JL; Vu C; Laugero KD; Parkes DG; Young AA
Int J Obes (Lond); 2006 Sep; 30(9):1332-40. PubMed ID: 16534527
[TBL] [Abstract][Full Text] [Related]
33. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent.
Lee KC; Chae SY; Kim TH; Lee S; Lee ES; Youn YS
Regul Pept; 2009 Jan; 152(1-3):101-7. PubMed ID: 18951927
[TBL] [Abstract][Full Text] [Related]
34. Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris.
Huang YS; Chen Z; Chen YQ; Ma GC; Shan JF; Liu W; Zhou LF
J Pept Sci; 2008 May; 14(5):588-95. PubMed ID: 17994612
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
Yu L; Li K; Liu X; Chen C; Bao Y; Ci T; Chen Q; Ding J
J Pharm Sci; 2013 Nov; 102(11):4140-9. PubMed ID: 24114868
[TBL] [Abstract][Full Text] [Related]
36. Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan.
Ahn S; Lee IH; Lee E; Kim H; Kim YC; Jon S
J Control Release; 2013 Sep; 170(2):226-32. PubMed ID: 23747732
[TBL] [Abstract][Full Text] [Related]
37. Decanoic acid-modified glycol chitosan hydrogels containing tightly adsorbed palmityl-acylated exendin-4 as a long-acting sustained-release anti-diabetic system.
Lee C; Choi JS; Kim I; Byeon HJ; Kim TH; Oh KT; Lee ES; Lee KC; Youn YS
Acta Biomater; 2014 Feb; 10(2):812-20. PubMed ID: 24140611
[TBL] [Abstract][Full Text] [Related]
38. Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015).
Park EJ; Lim SM; Lee KC; Na DH
Expert Opin Ther Pat; 2016 Jul; 26(7):833-42. PubMed ID: 27196800
[TBL] [Abstract][Full Text] [Related]
39. PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction.
Sun Z; Tong G; Kim TH; Ma N; Niu G; Cao F; Chen X
Theranostics; 2015; 5(3):240-50. PubMed ID: 25553112
[TBL] [Abstract][Full Text] [Related]
40. Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action.
Levy OE; Jodka CM; Ren SS; Mamedova L; Sharma A; Samant M; D'Souza LJ; Soares CJ; Yuskin DR; Jin LJ; Parkes DG; Tatarkiewicz K; Ghosh SS
PLoS One; 2014; 9(2):e87704. PubMed ID: 24503632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
